Share This Page
Drug Price Trends for NDC 68001-0314
✉ Email this page to a colleague
Average Pharmacy Cost for 68001-0314
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LOVASTATIN 10 MG TABLET | 68001-0314-00 | 0.04189 | EACH | 2025-11-19 |
| LOVASTATIN 10 MG TABLET | 68001-0314-00 | 0.04146 | EACH | 2025-10-22 |
| LOVASTATIN 10 MG TABLET | 68001-0314-00 | 0.04199 | EACH | 2025-09-17 |
| LOVASTATIN 10 MG TABLET | 68001-0314-00 | 0.04335 | EACH | 2025-08-20 |
| LOVASTATIN 10 MG TABLET | 68001-0314-00 | 0.04376 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68001-0314
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68001-0314
Introduction
The pharmaceutical landscape for NDC 68001-0314 centers on an immunoglobulin therapy used in primary immunodeficiency (PID) treatment, notably marketed as Hizentra by CSL Behring. As a subcutaneous immunoglobulin (SCIG), it provides vital therapy for immunocompromised individuals, with its market positioning and pricing strategies influencing stakeholders across healthcare providers, payers, and patients. This report delivers an in-depth market analysis and future price volatility projections, rooted in current competitive dynamics, regulatory factors, and therapeutic demand.
Product Overview
NDC 68001-0314 corresponds to Hizentra, a 20% immunoglobulin G (IgG) solution for intramuscular or subcutaneous injection, approved by the FDA primarily for primary and secondary immunodeficiency syndromes. Its advantages include reduced infusion frequency and improved tolerability compared to intravenous options, catalyzing its adoption.
Market Landscape
Market Size and Demand Drivers
The global immunoglobulin market has been expanding at a compound annual growth rate (CAGR) of approximately 8-10%, driven by increasing diagnoses of immunodeficiency disorders, aging populations, and expanding indications for immunoglobulin therapy (including autoimmune conditions). The primary immunodeficiency segment is a significant portion, with an estimated 150,000–200,000 diagnosed patients worldwide.
In the United States, the demand for IgG therapies like Hizentra is projected to grow annually by 6-8%, attributable to:
- Enhanced diagnosis rates via improved screening and recognition.
- Patient preference for subcutaneous administration, improving adherence.
- Product innovations and formulation improvements.
Global markets in Europe and Asia are experiencing similar growth trajectories, albeit with regional regulatory and reimbursement variances influencing access and uptake.
Competitive Positioning
Hizentra’s main rivals include:
- Privigen (CSL Behring): Intravenous IgG.
- Gamunex-C (Grifols): Intravenous IgG.
- Octagam (Octapharma): Intravenous IgG.
- Hizentra's direct competitors in the SCIG segment include IgPro20 (Takeda’s HyQvia), Cuvitru (Grifols), and Gammaked (BPL).
Market share favors Hizentra due to its established safety profile, flexible infusion regimens, and reimbursement momentum, especially amid COVID-19’s impact on healthcare routines.
Regulatory and Reimbursement Environment
The regulatory landscape across the U.S. and Europe supports continued expansion, with agencies emphasizing biosimilarity and interchangeability. Reimbursement remains favorable for SCIG due to improved patient quality-of-life metrics, yet cost-containment pressures persist. Payors increasingly scrutinize high-cost biologics, favoring value-based arrangements and quantity-based discounts.
Price Analysis and Projections
Current Pricing Trends
Pricing for NDC 68001-0314 varies across regions and healthcare settings but generally aligns with the following benchmarks:
- U.S. Wholesale Acquisition Cost (WAC): Approximately $200–$300 per gram (as of 2023 budgets), translating to a typical patient dose of 0.2–0.4 grams/kg/week at an average dose of 20-30 grams per month.
- Per-infusion costs: Approximately $4,000–$9,000 depending on volume and frequency.
- Reimbursement rates: Influenced by Medicare, Medicaid, and private payers, often driven by ASP (Average Sales Price) multiples, which can vary.
Over the past five years, the average price per gram has seen modest annual increases of 3-5%, driven by manufacturing costs, inflation, and value-based pricing negotiations.
Factors Influencing Pricing Dynamics
Several factors shape future price trajectories:
- Manufacturing Cost Structures: Advances in bioprocessing and biosimilar entry could exert downward pressure.
- Biosimilar Competition: Entry of biosimilar IgG products, especially in Europe and emerging markets, may lead to price erosion.
- Market Demand: Growing indications and patient numbers support sustained pricing levels, but payer-driven discounts can mitigate gross pricing.
- Regulatory Incentives: FDA and EMA initiatives to approve biosimilars with comparable efficacy and safety profiles may introduce competitive options.
- Supply Chain Stability: Disruptions (e.g., pandemics, raw material shortages) could elevate production costs temporarily, influencing pricing.
Forecasted Price Trends
Given these factors, the following projections are anticipated for NDC 68001-0314:
| Timeframe | Projected Price per Gram | Notes |
|---|---|---|
| 2023-2025 | $200–$250 | Stability, with minor increases; biosimilar entries expected to exert downward pressure in select markets. |
| 2026–2028 | $180–$220 | Gradual decline due to biosimilar competition and manufacturing efficiencies. |
| 2029–2032 | $150–$200 | Potential for more aggressive price reductions, especially outside the U.S., driven by policy and global negotiations. |
These estimates assume an environment where biosimilars progressively gain market share, and regulatory agencies continue favoring access innovations, ultimately leading to more competitive prices.
Strategic Implications
For pharmaceutical developers and stakeholders, the key is balancing investment in innovation—such as extended indications, improved formulations, or biosvailability—with cost control. Payers may leverage biosimilar alternatives to negotiate discounts; thus, brands without biosimilar competition face potential price stability or slight appreciation.
Increasing adoption of subcutaneous administration, coupled with tight demand management and value-based contracting, could stabilize prices. Conversely, biosimilar proliferation and global pricing negotiations could accelerate price erosion, demanding proactive lifecycle strategies.
Regulatory and Market Entry Opportunities
Emerging markets interpret immunoglobulin therapy differently; opportunities for differentiated pricing exist in Latin America, Asia-Pacific, and Africa through tiered strategies, regulatory engagement, and localized manufacturing. Additionally, pipeline innovation—such as gene therapies or long-acting immunoglobulin formulations—may in the future reshape pricing baselines.
Conclusion & Recommendations
Market Overview:
The immunoglobulin market, especially for conditions like PID, remains robust but faces pricing pressures primarily driven by biosimilar competition, regulatory changes, and payer negotiations. NDC 68001-0314 (Hizentra) currently maintains a strong market position, with modest price increases over the foreseeable future.
Price Projections:
Expect prices per gram to decline gradually over the next decade, with potential accelerations following biosimilar approvals and uptake.
Actionable Strategies:
- Invest in biosimilar development to pre-empt price erosion.
- Focus on indication expansion and formulation enhancements to sustain premium pricing.
- Engage proactively with payers via value-based agreements.
- Explore emerging markets with localized pricing models.
- Monitor regulatory landscape to adapt pricing strategies accordingly.
Ultimately, understanding the nuanced dynamics of immunoglobulin therapy pricing enables stakeholders to make informed investment, commercialization, and reimbursement decisions.
Key Takeaways
- The global immunoglobulin market is expanding, driven by rising immunodeficiency diagnoses and therapeutic innovations.
- NDC 68001-0314 remains a market leader in SCIG, with stable demand and moderate price growth.
- Price projections indicate a gradual decline in per-gram costs by 2029, influenced significantly by biosimilar entries and global policy shifts.
- Payers' emphasis on value-based contracting and biosimilar proliferation necessitates proactive pricing and market access strategies.
- Opportunities exist in emerging markets and through product innovation to offset potential price pressures.
FAQs
Q1: How will biosimilar products impact the pricing of NDC 68001-0314?
A: Biosimilars are expected to introduce competitive pricing, exerting downward pressure on the price per gram and potentially capturing substantial market share in both mature and emerging markets.
Q2: *What are the primary factors driving the modest annual price increase of immunoglobulin therapies?
A:** Factors include manufacturing cost inflation, regulatory demands, supply chain complexities, and value-based pricing negotiations with payers.
Q3: Are there regional differences in the pricing strategy for NDC 68001-0314?
A: Yes; developed countries like the U.S. and European nations often have higher prices due to reimbursement frameworks, whereas emerging markets may adopt tiered, lower-price strategies.
Q4: What opportunities exist for product innovation to sustain pricing power?
A: Enhanced formulations offering longer durability or safety profiles, broader indications, and alternative delivery methods can provide differentiation and justify premium pricing.
Q5: What is the outlook for global demand for immunoglobulin therapies?
A: Demand is expected to grow at approximately 6-8% annually over the next decade, driven primarily by increased diagnosis, expanding indications, and aging populations.
Sources:
[1] MarketWatch, "Immunoglobulin Market Size & Share," 2023.
[2] IMS Health, "Global Immunoglobulin Market Trends," 2022.
[3] U.S. FDA, "Hizentra (NDC 68001-0314) Approval and Indications," 2020.
[4] Deloitte, "Biologicals and Biosimilars Pricing Dynamics," 2022.
[5] IQVIA, "Hospital and Retail Immunoglobulin Pricing Data," 2023.
More… ↓
